Scarica l'app Stockscreener
16.38
2.67%
-0.45
Precedente Chiudi:
$16.83
Aprire:
$16.97
Volume 24 ore:
259.80K
Relative Volume:
0.37
Capitalizzazione di mercato:
$897.33M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-2.50%
1M Prestazione:
-4.49%
6M Prestazione:
+78.04%
1 anno Prestazione:
-3.22%
Intervallo 1D:
$16.07
$17.00
Intervallo di 1 settimana:
$15.90
$17.09
Portata 52W:
$7.80
$19.71
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-468-4219
Indirizzo
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Confronta BCAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
16.38 | 921.98M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Mizuho | Neutral |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-05-23 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Iniziato | Wells Fargo | Underweight |
| 2025-02-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-10-08 | Iniziato | Stifel | Buy |
| 2024-10-08 | Iniziato | TD Cowen | Buy |
Mostra tutto
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
Bicara Therapeutics (NASDAQ:BCAX) Trading 3.9% Higher – Here’s Why - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 3.9%Still a Buy? - MarketBeat
Straddle Buy Call Buy Put at same strikeEarnings Call Summaries & Exceptional Return Growth - bollywoodhelpline.com
Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock - Investing.com India
Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock By Investing.com - Investing.com Nigeria
Bicara Therapeutics (BCAX) Valuation After Dual Biotechnology Index Additions - Yahoo Finance
How Bicara's Dual Biotech Index Additions Will Impact Bicara Therapeutics (BCAX) Investors - simplywall.st
The Bull Case For Bicara Therapeutics (BCAX) Could Change Following Dual Inclusion In Major Biotech Indices - Yahoo Finance
Bicara Therapeutics Inc.(NasdaqGM: BCAX) added to NASDAQ Biotechnology Index - marketscreener.com
Bicara Therapeutics Inc.(NasdaqGM:BCAX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Is Bicara Therapeutics Inc. stock a defensive play in 2025July 2025 PostEarnings & Intraday High Probability Setup Alerts - Улправда
Can Bicara Therapeutics Inc. stock rebound after recent weaknessEarnings Overview Summary & Verified Swing Trading Watchlist - ulpravda.ru
Bicara Therapeutics (NASDAQ:BCAX) Raised to Hold at Mizuho - Defense World
Is Bicara Therapeutics Inc. stock trading at a premium valuationInsider Buying & AI Forecast for Swing Trade Picks - Улправда
Will Bicara Therapeutics Inc. stock deliver better than expected guidanceEarnings Recap Report & Weekly High Potential Alerts - Улправда
Published on: 2025-12-19 16:38:22 - Bölüm Sonu Canavarı
Bicara Therapeutics (NASDAQ:BCAX) Raised to "Hold" at Mizuho - MarketBeat
Will Bicara Therapeutics Inc. stock continue dividend increasesJuly 2025 Sentiment & Fast Entry High Yield Stock Tips - Улправда
What makes Bicara Therapeutics Inc. stock attractive to growth fundsFed Meeting & Technical Pattern Recognition Alerts - Улправда
Can Bicara Therapeutics Inc. stock reach $100 price target2025 Earnings Impact & Long-Term Investment Growth Plans - ulpravda.ru
Mizuho Initiates Coverage of Bicara Therapeutics (BCAX) with Neutral Recommendation - Nasdaq
Mizuho Initiates Bicara Therapeutics at Neutral With $18 Price Target - marketscreener.com
Bicara Therapeutics (BCAX) Receives Neutral Rating from Mizuho | - GuruFocus
Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating - Investing.com India
Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating By Investing.com - Investing.com Canada
Bicara Therapeutics initiated with a Neutral at Mizuho - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 12,500 Shares - MarketBeat
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 - The Manila Times
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bicara Therapeutics Earns Relative Strength Rating Upgrade - Investor's Business Daily
Bicara announces preliminary data from phase 1b cohort of ficerafusp alfa - MSN
There is no doubt that Bicara Therapeutics Inc (BCAX) ticks all the boxes. - setenews.com
Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Bicara stock maintains Buy rating at Stifel after ESMO-Asia data - Investing.com Australia
Published on: 2025-12-09 02:41:05 - moha.gov.vn
Promising Efficacy and Investment Potential for Bicara Therapeutics’ FICERA in Combination with Keytruda - TipRanks
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation - TipRanks
Bicara Therapeutics Reports Promising Phase 1b Data - TipRanks
Bicara Therapeutics Advances Dose Optimization of Potential Neck, Head Cancer Treatment - marketscreener.com
Bicara Therapeutics Inc Announces Preliminary Phase 1b Data - TradingView — Track All Markets
Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics’ Buy Rating - TipRanks
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Non sono disponibili dati finanziari per Bicara Therapeutics Inc (BCAX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Bicara Therapeutics Inc Azioni (BCAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Raben David | Chief Medical Officer |
Dec 26 '25 |
Option Exercise |
3.79 |
19,789 |
74,996 |
55,286 |
| Hyep Ivan | Chief Financial Officer |
Dec 22 '25 |
Option Exercise |
3.79 |
9,200 |
34,866 |
154,555 |
| Hyep Ivan | Chief Financial Officer |
Dec 22 '25 |
Sale |
18.31 |
9,200 |
168,492 |
145,355 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):